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Abstract
Prostate cancer consists of secretory cells and a population of immature cells. The function of immature cells and their
mutual relation with secretory cells are still poorly understood. Immature cells either have a hierarchical relation to secretory
cells (stem cell model) or represent an inducible population emerging upon appropriate stimulation of differentiated cells.
Hepatocyte Growth Factor (HGF) receptor c-MET is specifically expressed in immature prostate cells. Our objective is to
determine the role of immature cells in prostate cancer by analysis of the HGF/c-MET pathway. Gene-expression profiling of
DU145 prostate cancer cells stimulated with HGF revealed induction of a molecular signature associated with stem cells,
characterized by up-regulation of CD49b, CD49f, CD44 and SOX9, and down-regulation of CD24 (‘stem-like signature’). We
confirmed the acquisition of a stem-like phenotype by quantitative PCR, FACS analysis and Western blotting. Further, HGF
led to activation of the stem cell related Notch pathway by up-regulation of its ligands Jagged-1 and Delta-like 4. Small
molecules SU11274 and PHA665752 targeting c-MET activity were both able to block the molecular and biologic effects of
HGF. Knock-down of c-MET by shRNA infection resulted in significant reduction and delay of orthotopic tumour-formation
in male NMRI mice. Immunohistochemical analysis in prostatectomies revealed significant enrichment of c-MET positive
cells at the invasive front, and demonstrated co-expression of c-MET with stem-like markers CD49b and CD49f. In
conclusion, activation of c-MET in prostate cancer cells induced a stem-like phenotype, indicating a dynamic relation
between differentiated and stem-like cells in this malignancy. Its mediation of efficient tumour-formation in vivo and
predominant receptor expression at the invasive front implicate that c-MET regulates tumour infiltration in surrounding
tissues putatively by acquisition of a stem-like phenotype.
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Introduction
Within the prostate epithelium, tissue homeostasis is mediated
by stem cells residing in the basal glandular epithelium [1]. After
asymmetric division stem cells give rise to transit-amplifying cells,
which are present in both basal and luminal epithelium, and which
finally differentiate into luminal secretory cells. Various membra-
nous markers are differentially expressed in stem and differentiated
cells in benign rodent and human prostate epithelium including
Sca-1
+, a6-integrin/CD49f
+, a2-integrin/CD49b
+, CD133
+,
CD117
+, CD44
+ and CD24
2 [2–9]. Combination of these
markers might further delimitate stem, transit-amplifying and
terminally differentiated cells in normal epithelium. For instance,
stem cells putatively express a2b1-integrin
+/CD133
+, transit-
amplifying cells are a2b1-integrin
+/CD133
2, and terminally
differentiated cells are a2b1-integrin
2/CD133
2 [3,7].
Cell populations with biological features resembling those of
benign stem cells have also been identified in malignant tumours
[10–13]. In prostate cancer, a2b1-integrin
+/CD133
+ cells possess
potency for self-renewal and multi-directional differentiation in
vitro [8,14]. In addition, CD44
+/CD24
2 cells isolated from
prostate cancer cell lines demonstrate high tumour-forming
potential in vivo [4]. In spite of their apparent variability in
clonogenic and tumour-initiating potential, the mutual relation
between immature and differentiated cells is still poorly under-
stood. In correspondence to their relation in normal tissues, a strict
hierarchic relation between so-called cancer stem cells (CSC’s) and
differentiated cells has been postulated [12–14]. According to this
model, CSC’s are direct and irreversible progenitors of differen-
tiated cells. Recently, however, it was demonstrated that
differentiated cells can acquire CSC features in mammary and
colon cancer [15,16]. Particularly, phenotypic and biological
characteristics contributed to stem cells can be gained, when more
differentiated cells undergo epithelial-mesenchymal transition
(EMT) either by forced depression of E-cadherin or by factors
secreted by the micro-environment such as Hepatocyte Growth
Factor (HGF) [15,16]. Since its exact nature and relation with
other cell types are still controversial, we refer to the cell
population displaying stem cell characteristics as stem-like cells.
HGF and its tyrosine kinase receptor c-MET are important
mediators of organogenesis, tissue regeneration and wound
healing [17]. Within the normal prostate epithelium, c-MET is
specifically expressed in basal and atrophic luminal cells, where it
putatively mediates regeneration of damaged secretory glands
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26753[18,19]. In prostate cancer, c-MET is present at low levels, with a
minority of cells displaying high protein expression [18,20,21].
Previously, others and we have shown that c-MET and basal cell
marker Keratin 5 are co-expressed within the same cell population
in prostate cancer [14,18]. Since the HGF/c-MET pathway has a
regulatory function in migration and invasion in vitro, we have
suggested that this cell population is specifically prone to
infiltration in surrounding tissues [18,22].
Little is known on the role of c-MET in relation to stem-like
cells in prostate cancer and how in vitro studies on stem-like cells
translate to actual cancer in patients. In this study, we demonstrate
that activation of c-MET leads to induction of a stem-like
phenotype in prostate cancer. Knock-down of c-MET further
strongly reduced tumour-formation in nude mice. Finally, we
demonstrate that c-MET is preferentially expressed at the
perimeter of human prostatectomy specimens and is co-localized
with its down-stream targets a2-integrin and a6-integrin. These
data indicate that stem-like cells mediate tumour expansion at the
invasive front of prostate cancer.
Materials and Methods
Ethics statement
The study was approved by the national Animal Experiment
Committee (DEC; 102-08-01; EUR1396). All patient samples
were anonymously used after appropriate written informed
consent and under approval of the human ethics Institutional
Review Board (METC; MEC02.0957).
Cells and materials
DU145 prostate cancer cell line and human embryonic kidney
(HEK) 293T cells were purchased from the American Type
Culture Collection (ATCC, Rockville, MD, USA). DU145 was
maintained at 37uC/5% CO2 in RPMI 1640 containing 5% fetal
calf serum (FCS) and penicillin/streptomycin (P/S) (Lonza,
Verviers, Belgium). For stimulation experiments, DU145 cells
were seeded overnight in RPMI/FCS medium. After 1 day,
medium was replaced by 5% Dextran Charcoal (DCC) treated
RPMI (Sigma, St. Louis, MO, USA). After adaptation overnight,
HGF (25 ng/ml; Sigma) was added to the culture medium and
cells were harvested by incubation with 2 mM EDTA (Sigma) for
20 min. Small molecules SU11274 (1.0 mM; Sigma) and
PHA665752 (0.1 mM; Calbiochem, Nottingham, UK) dissolved
in dimethyl sulfoxide (DMSO) were used for c-MET inhibition.
Microarray analysis
DU145 cells were stimulated for 2, 8 and 24 hours with HGF or
vehicle, and RNA was isolated using RNAzol B reagent (Tel-test
Inc., Friendswood, USA). After RNA isolation with chloroform,
isopropanol and ethanol, DNA was digested using DNA-free kit
(Ambion, Huntingdon, UK). RNA quality and quantity were
measured using RNA 6000 Nano kit on a 2100 Bioanalyzer
(Agilent, Palo Alto, CA, USA). Samples with RNA integrity
numbers of .8.5 were selected. 5 mg of total RNA from stimulated
and control samples were used to prepare antisense biotinylated
RNA according to manufacturer’s one-cycle protocol (Affymetrix,
Santa Clara, CA, USA). Hybridization to Affymetrix Human
U133plus2.0 GeneChips (54,614 probe sets, representing approx-
imately 47,000 transcripts), staining, washing, and scanning
procedures were performed as described by Affymetrix (Affyme-
trix, Santa Clara, CA, USA), and performed by Erasmus MC
Center for Biomics. Microarray data were processed and
normalized using the Affymetrix Microarray Suite software.
RMA quantile normalization was performed and expression
values (EVs) between arrays were normalized by setting the
average of each of the 6 arrays to 150; values ,30 were set to 30.
For each time point
2log ratios between HGF and vehicle treated
cells were calculated. Array data are MIAME compliant and have
been submitted to GEO (GSE16659). Linkage to other databases
was performed using SRS7; the Treeview program was used for
generating heatmap pictures [23,24].
Quantitative real-time PCR
Quantitative real-time PCR was performed using Taqman RXN
PCR Core Reagents including MQ, Taq Buffer, MgCl2,d N T P ,
Amplitaq G (Applied Biosystems, Foster City, CA, USA). The follow-
ing probes were used: Hs02379687_s1 (CD24); Hs00174139_m1
(CD44); Hs01041017_m1 (CD49f); Hs00165814_m1 (SOX9);
Hs00158148_m1 (CD49b). The amount of target gene was
normalized to GAPDH (Hs99999905_m1).
For analysis of c-MET inhibitors on CD49b, total RNA was
isolated with RNAzol B reagent (Tel-Test) according to the
manufacturer’s protocol. RT reaction was performed with
oligo(dT)12–18 primer (Invitrogen, La Jolla, CA). After addition
of first-strand buffer, dithithreitol, dNTPs and RNAsin, RT
reactions were initiated by MMLV-RT (Invitrogen) and incubated
for 1 hour at 37uC. Quantitative PCR was performed using
SYBR-green mastermix (Applied Biosystems). CD49b forward 59-
CAG GCA CAC CAA AGA ATT GA-39, reverse 59-GAA GAA
GCC GAG CTT CCA TA-39, GAPDH forward 59-ACT GTG
GTC ATG AGT CCT TC-39, reverse 59-CAT GTT CGT CAT
GGG TG-39, and PBGD forward 59-CAT GTC TGG TAA CGG
CAA TG-39 and reverse 59-GTA CGA GGC TTT CAA TGT
TG-39. Signals were analyzed by ABI Prism 7700 system (Applied
Biosystems). Quantity of target genes was determined using
standard curves from serial dilutions. For determination of
Notch-receptors and ligands, RT-PCR was performed using the
primer sets and cycli as depicted in Table S1 at an annealing
temperature of 60uC.
Flow cytometry and Western blotting
For analysis of membranous proteins 0.5610
6 DU145 cells were
incubated with anti-CD49b (1:500; Chemicon, Hampshire, UK),
anti-CD49f (1:10,000; Abcam, Cambridge, UK), anti-CD44-
FITC (1:200; BD, Franklin Lakes, NJ, USA), anti-CD24-PE
(1:10; BD) and anti-CD133-PE (clone AC133; 1:100; Miltenyi-
biotec; Bergisch Gladbach, Germany), in 50 ml PBS/2% FCS for
30 min. on ice. After washing, cells were incubated with secondary
antibodies labelled with Alexa Fluor 488 (1:500) for 15 min. After
suspension in 300 ml PBS/2% FCS with Hoechst 33258 (2 mg/ml)
to select for living cells, protein expression was measured using a
FACSAria flow cytometer (BD) equipped with three lasers (407,
488 and 633 nm).
For analysis of SOX9 and c-MET protein, stimulated and
control cells were lysed in RIPA buffer (10 mM tris pH 7.4,
150 mM NaCl, 1% Triton 6100, 1% deoxycholate, 0.1% SDS,
5 mM EDTA) containing proteinase inhibitors (Complete; Roche,
Basel, Switzerland). Protein concentrations were measured using
Biorad protein reagents (Biorad Laboratories, Mu ¨nchen, Ger-
many). 40 mg of total protein was loaded on a 10% SDS-PAGE gel
and transferred to nitrocellulose paper (Protan, Schleicher and
Schuell, Dassel, Germany). After blocking in 5% NFDM/TBST
(Protifar, Nutricia, Zoetermeer, The Netherlands) for 1 hour, blots
were incubated at 4uC overnight with 0.2 mg/ml anti-SOX9
(clone AF3075; R&D, Minneapolis, USA) or 1:1,000 c-MET
(clone C12; Santa Cruz). After washing, blots were incubated with
1:1,000 anti-goat-HRP or anti-rabbit-HRP (Dako, Glostrup,
c-MET Induces Stem-Like Cells in Prostate Cancer
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Blotting Substrate (Roche) and quantified with ImageJ program.
MTT and cell adhesion assays
5.0610
3 DU145 cells were stimulated in 96-wells plates with
25 ng/ml HGF for 0, 3 and 6 days. Cultures were incubated with
Thiazolyl blue tetrazolium bromide (MTT 5 mg/ml; Applichem,
Darmstadt, Germany) for 4 hours, after which the metabolic
product was suspended in 100 ml buffered DMSO and measured
at 570 nm with a BIO-RAD 550 microplate reader (Biorad). For
quantification of cell adhesion, 3.0610
5 stimulated DU145 cells
were seeded on 12-wells plates coated with collagen I (Becton
Dickinson Labware, Bedford, UK). After adhesion for 15 min.,
plates were washed, incubated with 1 ml DCC medium containing
5 mg/ml MTT, and optical density was determined.
Lentiviral infection
HEK 293T cells were seeded in flasks coated with 0.1% gelatin/
PBS and grown to 50–60% confluence. Lentiviral particles were
produced after transfection of HEK 293T cells with 20 mgo f
vector DNA (pLKO.1 shRNA, ID167, clone NM_000245.x-
502s1c1; Sigma) together with 15 mg pPAX2 and 6 mg pMD2G
using CaPO4 precipitation, after which dH2O, 2.5M CaCl2 and
HEPES buffered saline (pH 7.05) was added. The transfection
mixture was left to incubate for 20–30 min. at room temperature
before it was added to the HEK 293T cells. The shRNA lentivirus-
containing cell culture supernatants were collected 24 and
48 hours after transfection, and passed through a 0.45-mm filter.
To determine the transfection efficiency HEK 293T cells were
simultaneously transfected with Green Fluorescent Protein (GFP).
Scrambled shRNA (Sigma) was used as control. DU145 was then
infected with the collected virus (1:1) overnight and infected clones
were selected by dilutional cloning.
Orthotopic injection
1.0610
5 DU145 cells were injected in the dorsolateral lobe of
male nu/nu Naval Medical Research Institute (NMRI) mice
together with 1.0610
6 PrSC prostate fibroblasts in 20 ml RPMI/
DCC medium containing human HGF (25 ng/ml) [25]. Injections
were performed with a 30G microlance needle (Becton Dickinson,
Alphen a/d Rijn, The Netherlands) on a Luer tip microliter 700
syringe (Hamilton, Bonaduz, Switserland) after abdominal incision
under anesthesia. Tumour volume (TV) was monitored every
week by transrectal ultrasonography (Endosonics Europe BV,
Rijswijk, The Netherlands). Mice were sacrificed at a
TV.1000 mm
3 or after 3–4 months. The prostate was histolog-
ically analyzed together with abdominal lymph nodes and lungs.
Immunohistochemistry
Immunohistochemistry for c-MET was performed on 94
formalin-fixed, paraffin-embedded radical prostatectomies (RP).
Sections of 4 mm were dewaxed and rehydrated using xylene and
ethanol. Endogeneous peroxidase was quenched and antigen
retrieval was performed during 15 min. of microwave irradiation
(700 W) in Tris-EDTA (pH=9). Slides were incubated with rabbit
anti-human c-MET (1:100; C12; Santa Cruz) overnight at 4uC
and visualized using the EnVision system (DAKO). For quanti-
fication of c-MET, the presence of strongly positive cells was
scored at the perimeter, arbitrarily defined as the outer 2 mm of
the tumour and compared with the centre.
For co-localization studies, 6 liquid N2 frozen RP slides were
acetone-fixed and incubated with anti-c-MET (1:100), and mouse
anti-human CD49b (1:100; HAS-3; Abcam) or rat anti-human
CD49f (1:100; Abcam) overnight at 4uC. After washing, slides
were incubated with swine anti-rabbit biogenin (1:150; DAKO)
combined with anti-mouse or anti-rat antibody labelled with Alexa
488 (1:100) for 30 min., followed by avidin-Cy3 (1:100) complex
formation for 30 min. at room temperature.
Statistics
Growth effects of HGF and c-MET inhibitors were evaluated
with Student’s t-test. Immunohistochemical expression of c-MET
in RP was analyzed with Pearson x
2 test. Tumour formation in
mice were evaluated using both tests, all using SPSS version 15.0
(SPSS Inc, IL, USA). A two-sided p-value below 0.05 was
considered significant.
Results
Discovery of HGF/c-MET regulated genes
Previous RT-PCR and Northern blot analysis demonstrated
that c-MET is expressed in androgen-independent prostate cancer
cell lines DU145 and PC3, but not in androgen-dependent
LNCaP [18,20]. Stimulation of DU145 with HGF resulted in cell
scattering and migration in 2D-culture (Figure 1A), while stellate
sprouts form in 3D Matrigel matrices (Figure 1B). During
scattering, DU145 cells obtained a spindle form in contrast to
their normal epithelioid shape, while cell growth was significantly
inhibited by 21% after 3 days (p,0.003) and 10% after 6 days
(p=0.024)(Figure 1C). Although PC3 possesses c-MET protein,
HGF stimulation did not induce morphological changes (unpub-
lished observations) putatively due to its lack of a functional a-
catenin/E-cadherin complex [26].
To explore the molecular pathways relevant for c-MET
function in prostate cancer, we performed microarray expression
analysis of DU145 cells stimulated with HGF. Genes were selected
based on a two-fold up or down-regulation by at least one probe
set at the 24 hours’ time point and an average expression with a
1.41 fold difference. In total, 371 genes fulfilled these criteria of
which 238 were up- and 133 down-regulated by HGF (Table S2);
the top 20 up- and down-regulated genes are depicted in
Figure 2A.
We found that various membranous markers utilized for stem
cell selection were enhanced after 24 hours: a2-integrin/CD49b,
a6-integrin/CD49f and CD44, while CD24 was down regulated
(Figure 2B). The transcription factor SOX9 was also induced by
HGF. SOX9 is required for early differentiation of prostate
epithelium during embryogenesis and is reactivated in prostate
carcinogenesis implicating a relevant function in immature
prostate cells [27]. Expression of two other putative prostatic stem
cell markers CD133 and LGR5 was below detection limits
[14,28].
Validation of phenotypic stem-like cell induction
Regulation of stem cell associated genes by the HGF/c-MET
pathway was validated in three independent DU145 experiments
using quantitative PCR. A regulatory effect of HGF was
demonstrated for all selected genes (Figure 3). After 24 hours
of stimulation CD24 (0.4 fold) was down-regulated, while
CD49b (2.6 fold), CD49f (2.0 fold), CD44 (1.8 fold) and SOX9
(2.9 fold) were all enhanced. Subsequently, FACS analysis
confirmed up-regulation of membranous proteins CD49b,
CD49f, CD44, and suppression of CD24 (Figure 4A). The
effects on protein expression were most prominent for CD49b
with a general increase of 240%. Membranous expression of
CD49f and CD44 was only slightly enhanced after HGF
stimulation (22% and 26%, resp.). Since SOX9 is localized in
c-MET Induces Stem-Like Cells in Prostate Cancer
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regulation by HGF. As expected, expression of SOX9 protein
was strongly induced in stimulated DU145 cells up to 521% after
24 hours (Figure 4B).
Both CD44
+/CD24
2 and a2b1-integrin
+/CD133
+ profiles
select for stem-like cells in prostate cancer [4,14]. Upon HGF
stimulation, the CD44
+/CD24
2 population was enriched 3.25
fold (from 8% to 26%) combined with a 0.8 fold decrease (from
91% to 73%) of more mature CD44
+/CD24
+ cells (Figure 4C).
Selection for a2b1-integrin
+/CD133
+ cells is often pursued at first
by short-term adhesion to collagen I matrix, which selects for high-
integrin expressing cells [3]. To verify whether c-MET activation
enhances the fraction of rapidly attaching immature cells, we
quantified adhesion to collagen I after 15 min. Within this period,
0.037% (mean; SD 0.006%) of control cells attached to collagen I.
HGF activation of DU145 cells significantly (p,0.01) enriched for
rapidly adhering cells (mean 0.055%; SD 0.011%). With FACS
analysis, CD133 expression in DU145 was below detection limits
and not affected by HGF stimulation (data not shown).
HGF activates Notch pathway
Notch signalling plays an important role in the prostate
development and has been implicated in CSC function [29–31].
Analysis of the gene-expression profile demonstrated over-
expression (3.06) of the down-stream Notch target HES-1 upon
HGF stimulation. Therefore, we investigated the effects of HGF
on the Notch receptors and their ligands. We found that c-MET
activation led to up-regulation of Notch ligands Jagged-1 and
Delta-like (Dll) 4 (Figure 5). The ligand Jagged-2, receptors Notch-
2 and Notch-3 were unaffected, while Notch-1 receptor was down-
regulated upon HGF stimulation (data not shown), implicating
that Notch activation resulted from over-expression of ligands
Jagged-1 and Dll-4.
Inhibitors of c-MET block development of stem-like
phenotype. Recognition of immature cells in human
malignancies initiated development of specific pharmaceutical
agents targeting this biologically important population. The small
molecules SU11274 and PHA665752, which both inhibit c-MET
enzymatic activity completely blocked cell scattering in culture and
Figure 1. Effects of HGF on DU145 cell line. A, HGF induced transformation from epithelioid cell clusters towards single spindle cells in 2-
dimensional culture. B, In 3-dimensional Matrigel sprouts originated from compact cellular nodules after HGF stimulation. C, Cell proliferation is
inhibited by 21% (p,0.003) after 3 days and 10% (p=0.024) after 6 days of HGF stimulation (control black bars 2; HGF grey bars +). A, B Original
magnification 406.
doi:10.1371/journal.pone.0026753.g001
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HGF-mediated growth reduction was significantly reverted to the
baseline level (p,0.001) by PHA665752, but not by SU11274
(p=0.186)(Figure 6A). SU11274 (p,0.001) and PHA665752
(p=0.016) significantly reversed both the induction of CD49b
(Figure 6B) as well as the inhibition of CD24 (both p,0.001)
within 24 hours (Figure 6C). Because HGF only moderately
affected CD49f and CD44 levels, we did not evaluate
pharmacological effects on these markers.
Expression of c-MET modulates efficient tumour-
formation in vivo
For analyzing the role of c-MET in tumour-formation in vivo,w e
infected DU145 cells with lentivirus expressing shRNA targeting c-
MET receptor and selected three c-MET negative clones
(Figure 7A). The c-MET negative DU145 clones had similar
morphology as the parental line, when grown in 2D or 3D culture,
but did not react to HGF by scattering or formation of stellate
sprouts (data not shown). Orthotopic injection of parental DU145
resulted in 90% (9/10) tumour formation; these mice were
sacrificed with a TV of 1357 mm
3 (mean; range 1016–1860 mm
3)
after 42.6 days (mean; range 38–52 days). Control DU145 cells
infected with scrambled shRNA led to tumour formation in 100%
(5/5). These mice were all sacrificed due to large TV after 59 days
(mean; range 52–66 days)(Figure 7B). Significant reduction of
tumour formation occurred in the DU145 clones with silenced c-
MET. In total 55% (11/20) of the clones (6/10 Sh167#14, 3/5
Sh167#5 and 2/5 Sh167#6) gave rise to tumours, of which only
one was sacrificed due to large TV (1013 mm
3; 81 days). Fifteen
mice were sacrificed at 119 days (mean; range 109–124 days), of
which 6 had small tumours (mean TV 477 mm
3; range 137–
788 mm
3). Four mice died untimely between 52 to 102 days, all
showing small tumours (TV mean 225 mm
3; range 137–
304 mm
3)(Figure 7C). In none of the mice metastases were
observed. Taken together, functional c-MET mediated efficient
tumour formation in parental DU145 (p,0.02) and resulted in
significantly larger tumours in control DU145 cells (p,0.001).
Cells expressing c-MET are located at invasive front of
prostate cancer. Tumour cells with high c-MET expression
are specifically enriched at the invasive front of colorectal
carcinomas, where they mediate EMT, migration and matrix
invasion [34,35]. To determine c-MET expression at the invasive
front in prostate cancer, we compared the presence of high c-MET
expressing cells at the perimeter and the centre of well-fixed RP
specimens (N=94). Overall high c-MET expressing cells
(Figure 8A) were found in 37 cases (39.4%). The perimeter
contained more high c-MET expressing cells than the tumour
centre in 27 cases (73.0%). In 6 cases (16.2%) these cells were more
abundant in the centre, while in 4 RP’s (10.8%) there was no
difference in expression (Pearson x
2;p ,0.001). Expression of c-
MET in pre-existent benign basal cells within the entire slide
served as an internal control to exclude fixation-induced staining
artefacts. In total 25 cases revealed tumour expansion into extra-
prostatic fat tissue; in 10 extra-prostatic tumour areas (40.0%) high
c-MET expressing cells were encountered (Figure 8B).
Finally, co-expression studies were performed in RP specimens
to validate c-MET co-expression with stem-like cell markers in
patients. Immunofluorescent stainings for c-MET, CD49b and
CD49f demonstrated diffuse expression of all markers in basal cells
of pre-existent glands. Expression was low to absent in the vast
majority of normal and malignant luminal cells. Receptor c-MET
was expressed sporadically at high levels in single malignant cells.
These cells co-expressed CD49b and CD49f, indicating that c-
MET positive cells indeed co-express a stem-like cell phenotype in
human prostate cancer (Figure 9).
Discussion
At least three different cell populations can be discriminated in
human prostate cancer. While differentiated exocrine and neuro-
endocrine cells represent the predominant cell types, evidence is
increasing that a minor population of immature cells is
determinative for the biological behaviour of prostate cancer.
Analogical to normal glandular prostate epithelium, Collins et al.
Figure 2. Effects of HGF on gene-expression of DU145 cell line.
A, Top 20 up- and down-regulated genes after HGF stimulation for
24 hours, combined with respective gene-expression profiles after
stimulation for 2 and 8 hours. B, Effect of HGF on genes associated with
prostate stem cell phenotype.
doi:10.1371/journal.pone.0026753.g002
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+/CD133
+) and tran-
sit-amplifying cells (a2b1-integrin
+/CD133
2) in human prostate
cancer specimens by clonogenic, proliferative and differentiating
capacity in vitro [14]. Although CD133 is proposed as a general
marker for tumour progenitor cells, its specificity for actual tumour
stem cells is still under debate [10–12,14,36,37]. In colon cancer,
for instance, it has been proposed that the CD44
+/CD24
2/
CD133
2 profile represents the tumour stem cell population while
CD133
+ rather marks more differentiated cells [38]. Likewise, in
prostate cancer no agreement exists on whether CD133 enriches
for stem-like cells [8,39].
The HGF/c-MET pathway might play a key role in prostate
carcinogenesis and tumour progression [18,19]. In this study, we
found HGF to induce a phenotypic profile, which is strongly
associated with stem-like cells, namely up-regulation of CD44,
CD49b, SOX9 and CD49f, and down-regulation of CD24 on
RNA and protein levels. Further, c-MET activation led to a 3.25-
fold enrichment of CD44
+/CD24
2 cells, representing more
accurately the stem-like cell profile for breast and potentially
prostate cancer [4,13]. Activation of c-MET also activated the
Notch-signalling pathway by up-regulation of its ligands Jagged-1
and Dll-4, as well as the transcription factor SOX9, which are all
important for embryonic prostate development and have been
linked to malignant stem-like cells in several organs [27,31,40,41].
A limitation for investigating the HGF/c-MET pathway in
human prostate epithelium is the availability of relevant models.
Neither prostate cancer cell lines LNCaP, DuCap, VCap,
PC346C, 22RV1 nor primary benign epithelial cultures express
the c-MET receptor (data not shown). Furthermore, the human c-
MET receptor in prostate cancer xenografts has low sensitivity for
murine HGF, so that external human HGF sources or transgenic
mice are required for functional HGF/c-MET analysis [42]. The
only other c-MET positive cell line PC3 shows a stellate growth
pattern in 3D Matrigel and scattering in 2D culture, even without
stimulation of HGF. Therefore, its growth pattern without HGF
resembles the morphogenesis of DU145 with HGF stimulation.
We hypothesize that the specific PC3 growth pattern results from a
deficient E-cadherin complex function [26]. Interestingly, HGF/c-
MET can interfere with E-cadherin function in several ways: a)
up-regulation of Snail, Twist and Slug inhibit E-cadherin
transcription, b) tyrosine phosporylation of b-catenin leads to a
deficient membranous E-cadherin complex, and c) E-cadherin can
be cleaved extracellularly by matrilysin [43–46]. A functional E-
cadherin pathway therefore seems a prerequisite for HGF-induced
morphogenesis.
Considering the lack of alternative HGF/c-MET models for
prostate cancer, we specifically aimed at validating our results in
human prostate cancer specimens. While various genes have been
implicated in cancer stemness using in vitro and mice models,
investigation of respective markers is relatively rarely performed in
human specimens. Such validation might disclose discordances in
case a hypothesized stem cell marker is expressed in the vast
majority of cancer cells (for instance BMI-1), or is not expressed in
respective cancer tissue at all [47]. Previously, we have
demonstrated that c-MET is over-expressed in scattered prostate
cancer cells at radical prostatectomies [18]. In this study, we
demonstrate that high c-MET expressing cells preferentially occur
at the periphery of prostate cancer and in areas of extra-prostatic
Figure 3. Validation of stem cell associated gene-expression
after HGF stimulation. Quantitative real-time PCR confirmed
induction of CD49b, CD49f, CD44 and SOX9 mRNA, together with
down-regulation of CD24.
doi:10.1371/journal.pone.0026753.g003
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cells at the invasive front of colorectal cancer, as identified by their
nuclear expression of beta-catenin [34]. By immunofluorescent
double-labelling we were able to confirm that c-MET positive cells
co-expressed stem-like markers CD49b and CD49f in surgical
specimens. Despite the limited availability of c-MET models in
prostate cancer, these results indicate that HGF-mediated
induction of a stem-like phenotype is representative for human
disease.
The induction of a stem-like phenotype has recently also been
demonstrated in two other models. In immortalized human
mammary epithelial cells ectopic expression of Snail or Twist
transcription factors, which both inhibit E-cadherin expression, led
to EMT and induction of the CD44
+/CD24
2 stem cell phenotype
[15]. After EMT, the cell line exhibited properties of stem cells by
efficient formation of mammaspheres, differentiation towards
myo-epthelial and luminal cells, and high tumour-forming
capacity after malignant transformation with tumourigenic
V12H-ras oncogene. In colon cancer, myofibroblast-secreted
HGF restored a stem-like phenotype in more differentiated cells
in vitro and in vivo [16]. Our data are in line with these results,
demonstrating that stimulation of more mature prostate cancer
cells with HGF can induce a stem-like marker profile and high
tumour-formation in vivo. Interestingly, these observations support
Figure 4. Validation of stem cell associated proteins after HGF stimulation. A, FACS demonstrated up-regulation of CD49b (240%), CD49f
(22%), CD44 (26%), together with down-regulation of CD24 (269%) after HGF stimulation. Thin gray line represents labelling with secondary antibody
only (negative control), thin black line DU145 without HGF, and thick black line DU145 with HGF. B, Western blot showed enhancement of SOX9
expression upon HGF stimulation from 2 to 24 hours. C, FACS demonstrated induction of double-labelled CD44
+/CD24
2 DU145 cells (control 8%
versus HGF 26%).
doi:10.1371/journal.pone.0026753.g004
Figure 5. Effects of HGF on Notch pathway in DU145 cell line.
HGF stimulation led to over-expression of Notch ligands Jagged-1 and
Dll-4 RNA, and the down-stream Notch target HES-1.
doi:10.1371/journal.pone.0026753.g005
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e26753Figure 6. Effects of c-MET inhibitors on DU145 cell line. A, Cell proliferation is inhibited by SU11274 in both control (black bars 2) and HGF
stimulated cells (grey bars +), so that it did not reverse HGF mediated growth reduction (p=0.186). PHA665752 did not affect cell proliferation in
control cells, and blocked HGF induced growth inhibition (p,0.001). B, C, Both SU11274 and PHA665752 blocked HGF mediated induction of CD49b
(B) and inhibition of CD24 (C). Standard deviations represent three independent experiments.
doi:10.1371/journal.pone.0026753.g006
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e26753Figure 7. Reduced orthotopic tumour-formation of DU145 in NMRI mice after knock-down of c-MET. A, Three DU145 clones (5, 6, 14)
with low to negative c-MET protein expression (Western blot) were generated by stable shRNA infection. B, Orthotopic injection of 1.0610
5 DU145
with functional c-MET led to efficient tumour-formation in 9/10 parental (black) and 5/5 control DU145 cells (green) infected with scrambled RNA.
C, Orthotopic tumour-formation was significantly reduced in DU145 with low c-MET expression. A total of 6/10 DU145Sh167#14 (black), 3/5
DU145Sh167#5( green) and 2/5 DU145Sh167#6( red) injections resulted in tumour-formation. Only one tumour reached a TV of 1000 mm
3 during
the study period of 52–124 days.
doi:10.1371/journal.pone.0026753.g007
Figure 8. Immunohistochemical expression of c-MET in human prostate cancer. c-MET is highly expressed in scattered prostate cancer cells
(A), and particularly at invasive fronts within peri-prostatic fat tissue (B); arrowheads indicate positive cells. Original magnification 1006.
doi:10.1371/journal.pone.0026753.g008
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it is well known that c-MET activation leads to enhanced invasive
capacity together with secretion of matrix degrading proteins such
as uPA, MMP-1 and MMP-9, we now demonstrate that a stem-
like phenotype is acquired simultaneously [18,48,49]. Klarmann et
al. also found such a relation as LNCaP cells invasive in Matrigel
obtained stem-like characteristics, while Collins et al. demonstrate
that a2b1-integrin
+/CD133
+ cells isolated from RP specimens
have high invasive capacity [14,50]. Taken together, these results
suggest that stem-like cells represent a temporary state-of-being
during tumour invasion. If appropriate stimulation such as HGF is
discontinued, cellular invasion might subsequently be terminated,
after which stem-like cells undergo differentiation.
In conclusion, activation of the HGF/c-MET pathway gives rise
to a stem-like phenotype, preferentially at the invasive front of
human prostate cancer. Stem-like cells therefore might represent a
dynamic and inducible population, mediating invasion at the
perimeter of prostate cancer. Inhibition of c-MET has potency in
blocking stem-like cell transition and therefore is a promising tool
for targeted therapy of prostate cancer.
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